Molecular Point-of-Care Testing for Respiratory Infections: A Comprehensive Literature Review (2006–2026)

TL;DR

This paper reviews advancements in molecular point-of-care testing for respiratory infections, highlighting its accuracy and speed compared to traditional lab testing.

Contribution

The study provides a comprehensive analysis of molecular POCT technologies and their clinical performance from 2006 to 2026.

Findings

Modern molecular POCT platforms achieve sensitivities of 88% to 100% and specificities of 98% to 100%.

Technologies like RT-PCR, LAMP, RPA, and CRISPR enable rapid detection of pathogens like SARS-CoV-2 and RSV.

Integration with portable devices and smartphones improves access in resource-limited settings.

Abstract

Molecular point-of-care testing (POCT) for respiratory infections has undergone remarkable advancement over the past two decades, driven by technological innovation and urgent clinical needs highlighted by the COVID-19 pandemic. This comprehensive systematic review was conducted following PRISMA 2020 guidelines, synthesizing evidence from 254 peer-reviewed studies published between 2006 and 2026, with detailed analysis of the 30 most relevant papers selected through a rigorous four-stage screening process. The review examines the evolution of molecular POCT technologies, including reverse transcription polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), and CRISPR-based detection systems. Key findings demonstrate that modern molecular POCT platforms achieve diagnostic performance comparable to laboratory-based testing, with sensitivities ranging from 88% to 100% and specificities from 98% to 100%, while delivering results in 15 to 80 min. These technologies enable rapid, accurate detection of major respiratory pathogens, including SARS-CoV-2, influenza A/B, respiratory syncytial virus (RSV), and atypical bacteria. The integration of microfluidic systems, portable devices, and smartphone-based analysis has expanded access to testing in resource-limited settings, emergency departments, and wearable platforms. This review provides critical insights for clinicians, researchers, and policymakers regarding the current state, clinical applications, and future directions of molecular POCT for respiratory infections.